MD Anderson Cancer Center
The University of Texas
Houston, TX
Accepting patients
TAPUR
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
- ROS1 Inhibitor
- Phase 2
Accepting patients
Larotrectinib
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
VMD-928
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- Phase 2
Accepting patients
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
- Pan-RAF Kinase Inhibitor
- Phase 2
Accepting patients
TL118
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
- Phase 2
Not yet accepting
Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
- Tyrosine Kinase (TK) Inhibitor
- Radiation
- Phase 2